摘要
目的探讨低分子肝素钙治疗冠脉综合征(ACS)的临床疗效与安全性。方法将104例患者随机平分为常规治疗对照组和加用低分子肝素钙治疗的治疗组进行疗效对比,疗程7d。结果经治疗后,两组病人都取得了一定的临床疗效,治疗组统计治疗总有效率治疗组96.2%,也明显优于对照组76.9%(P<0.05);治疗组不良反应发生率也低于对照组。结论低分子肝素联合治疗冠脉综合征的临床疗效确切、安全,值得临床推广使用。
Objective To observe the clinical effect of low molecular weight heparin（LMWH）on acute coronary syndrome（ACS）. Method 104 cases were assigned with 52 cases control group and 52 cases treatment group.The control group with routine treatment, but the treatment group LMWH was subcutaneous injected with 5000u for twice a day on the basic treatment of control group. After 7days,observing the symptom and side effect of drugs, itesult The effective rate was 96.2% and 76.9% in treatment group and control group respectively. There are significant difference between tow group（P〈0.05）;and The treatment group side effect rate is lower than the control group. Conclusion it＇s accurate,safe to treat ACS with LMWH. And it is worth to spread clinically.
出处
《中外医疗》
2008年第12期11-12,共2页
China & Foreign Medical Treatment
